Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Newly Diagnosed Medulloblastoma, PNET, or ATRT
NCT00085202Phase 3Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Aug 2003
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Cytokines & Interferons
- Countries
- 3
01
Overview
A Phase 3 trial of vincristine sulfate liposome injection, Cisplatin micelle injection (HA132), cyclophosphamide, filgrastim in medulloblastoma, supratentorial primitive neuroectodermal tumor (sPNET), Atypical teratoid rhabdoid tumor (ATRT), sponsored by St. Jude Children's Research Hospital. Started Aug 2003; status: completed.
02
Drugs
vincristine sulfate liposome injectionCisplatin micelle injection (HA132)cyclophosphamidefilgrastim
03
Conditions
medulloblastomasupratentorial primitive neuroectodermal tumor (sPNET)Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT00085202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085202.